Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
OBJECTIVE
The aim of the present study was to determine whether the serum levels of a bone formation marker, i.e., the carboxy-terminal propeptide of type I procollagen (PICP), and a bone resorption marker, i.e., the carboxy-terminal telopeptide of type I collagen (ICTP) have prognostic value in prostate cancer patients with bone metastasis, compared with alkaline phosphatase (ALP) and prostate-specific antigen (PSA).


METHODS
The serum levels of PICP, ALP, ICTP and PSA were examined in 116 untreated prostate cancer patients (40 patients with bone metastasis, 76 patients without bone metastasis), and the prognoses of the patients with bone metastasis were evaluated using univariate and multivariate analyses.


RESULTS
The bone metastasis patients with low PICP or ALP values had significantly better outcomes compared to the bone metastasis patients with high PICP or ALP values. A multivariate analysis of PICP, ICTP, ALP, PSA and the patients' age revealed that PICP and patients' age were important prognostic factors for survival. The pretreatment levels of ICTP and PSA did not show any substantial relation to the prognosis of these patients.


CONCLUSIONS
The results suggest that the pretreatment serum bone formation marker is an important prognostic indicator for prostate cancer patients with bone metastasis.
Department of Urology, School of Medicine, Chiba University, Chiba, Japan.
S
S
Akimoto
H
H
Inomiya
Y
Y
Furuya
K
K
Akakura
H
H
Ito
D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood* / Q000556:secondary* / Q000628:therapy; D001862:Bone Resorption / Q000097:blood*; D002715:Chlormadinone Acetate / Q000008:administration & dosage / Q000627:therapeutic use; D003094:Collagen / Q000097:blood; D024042:Collagen Type I; D004967:Estrogens / Q000008:administration & dosage / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides / Q000097:blood; D011347:Procollagen / Q000097:blood; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000628:therapy
D014408:Biomarkers, Tumor; D024042:Collagen Type I; D004967:Estrogens; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; D045167:Progesterone Congeners; C052929:collagen type I trimeric cross-linked peptide; C042813:procollagen type I carboxy terminal peptide; D002715:Chlormadinone Acetate; D007987:Gonadotropin-Releasing Hormone; D003094:Collagen; D000469:Alkaline Phosphatase; D017430:Prostate-Specific Antigen